Connect with us


Best Penny Stocks to Buy Today? 3 That Climbed in Premarket

Which penny stocks are you watching today?
The post Best Penny Stocks to Buy Today? 3 That Climbed in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information |



3 Premarket Gaining Penny Stocks to Watch Right Now 

With blue chips and penny stocks climbing slightly during premarket, investors are excited about the future. The recent movement could be due to the better-than-expected CPI news from last month. Prior to this, we were witnessing major stock market volatility with prices gapping up and down substantially in any given trading day. 

So, while we’re are no where near being out of the woods yet in terms of price fluctuations, the gains of the past few days are a welcomed sign. With penny stocks, we have to understand that large economic factors will continue to play a major role in how they trade. And because of this, it is crucial to consider what will shift in the market moving forward. 

[Read More] 3 Penny Stocks to Watch Under $1 Right Now

Right now, many investors believe that 2022 could be a positive year for the stock market. This was echoed by finance mogul, Jamie Dimon, who stated a few days ago that the stock market could see new highs this year. While there is more unknown than known right now, the positivity being echoed around penny stocks is encouraging. So, with all of this in mind, let’s take a look at three penny stocks that climbed during premarket trading today. 

3 Penny Stocks That Climbed During Premarket Trading 

  1. OLB Group Inc. (NASDAQ: OLB
  3. Puma Biotechnology Inc. (NASDAQ: PBYI

OLB Group Inc. (NASDAQ: OLB) 

During premarket trading, shares of OLB stock shot up by over 8.8% to $2.47 per share. Despite a one year drop of roughly 56%, we are witnessing a small bullish turnaround with OLB Group right now. So, what does the company do and why are shares up right now? 

Well, the big news from OLB comes as it announced the potential delivery of an additional 400 Antminer S19K Pro cryptocurrency mining machines this month. The company states that it should be able to produce roughly $1 million in monthly revenue when its 1,000 miners are fully deployed and operational. 

“Upon delivery of all the machines, these 400 Antminer will bring our total cryptocurrency mining machine count to 1,000. We expect to be periodically ordering additional machines on an ongoing basis.” 

The CEO of OLB Group, Ronny Yakov

While cryptocurrency has crashed in the past few weeks, over the last few days, we’ve seen the market return to its bullish nature. Outside of this, OLB operates in eCommerce as a Fintech company. It provides Bitcoin mining, cloud services, customer service, sales reporting, and much more. So, as a potentially diversified play with exposure to the cryptocurrency industry, many investors are keeping an eye on the company. But, whether it deserves a spot on your list of penny stocks to watch is up to you. 


Up by around 14% in premarket trading are shares of BTCS stock. While this may seem like a lot, shares of the tech company have shot up by a staggering 85% in the past five days. Before we get into why shares are climbing today, it’s worth looking at what BTCS does. BTCS Inc. is a tech company working in the field of blockchain and digital assets. 

[Read More] Best Penny Stocks To Buy Now? 4 On Webull With Bullish User Ratings

The company claims that it is the first pure-play U.S. publicly traded company to focus on blockchain tech. Today, BTCS announced that it has added Algorand to its staking operations. The Algorand blockchain allows for asset development, smart contracts, atomic swaps and more. 

“More than 500 global organizations leverage Algorand’s technology – from university partners (MIT, UC Berkeley, Peking University), to ecosystem players (Orion Protocol, Chainalysis, Hummingbot), to key stakeholders (Union Square Ventures, Cumberland Advisors), to government enterprises (Marshall Islands). Given this, we believe ALGO is a great addition to our blockchain infrastructure efforts.” 

The COO of BTCS, Michal Handerhan

This is very exciting news, especially considering the rising price of cryptocurrency right now. With this in mind, will BTCS be on your penny stocks watchlist moving forward?


Puma Biotechnology Inc. (NASDAQ: PBYI) 

Moving out of the tech industry, we see Puma Biotechnology. Puma Biotech is a company focused on the development and commercialization of products used to fight cancer. This includes PB272, PB357, and many more. Yesterday, the company announced that the National Comprehensive Cancer Network or NCCN has included two important changes to its Clinical Practice Guidelines in Oncology for treating breast cancer in 2022. The changes involve its compound NERLYNX or neratinib. 

“The NCCN guidelines are utilized by many institutions, practices and clinicians who treat breast cancer patients. These updates help to increase the awareness of neratinib within the guidelines and should further support neratinib as an appropriate option to reduce the risk of recurrence for patients battling HER2-positive breast cancer.”

The CEO of Puma Biotechnology, Alan H. Auerbach

Right now and over the past two years, there has been a major emphasis on biotech penny stocks. While PBYI is not working on anything related to Covid right now, the company is seeing heightened popularity in 2022. With its sizable gain during premarket trading today, do you think that PBYI stock is worth buying right now or not?


Which Penny Stocks Are You Watching Right Now?

If you’re looking for the best penny stocks to buy in 2022, there are hundreds of options to choose from. But, to stay ahead of the game, investors need to have a thorough and consistent understanding of what’s going on in the stock market. Right now, the main contributing factor to market movement is the pandemic and specifically, the Omicron variant. 

[Read More] 3 Short Squeeze Penny Stocks To Buy For Under $5 Right Now

While hope for the end of the pandemic has been on the rise, we’ve also seen a sharp uptick in case numbers over the last few weeks. In addition to this, the economic state of the U.S. with factors such as inflation, unemployment, and interest rates, is also important to consider. So, while investing in 2022 is not easy, making money with penny stocks is possible. Considering all of this, which penny stocks are you watching right now?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

The post Best Penny Stocks to Buy Today? 3 That Climbed in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical…



According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion.

Pfizer, too, acquired Global Blood Therapeutics 

Pfizer wants to close a deal soon, but there are still other interested parties, according to the article.

Global Blood Therapeutics, which manufactures Oxbryta, the blood disorder medication, saw its shares jump 44%  on Friday afternoon to a two-year high. As of Thursday’s closing, the company’s market cap was $3.12 billion.

A spokesman for Global Blood stated the company does not “comment on market rumors or speculation,” while Pfizer declined to respond on the matter.

With plenty of cash left over after selling its COVID-19 vaccine, New York-based Pfizer is searching for deals that may generate billions of dollars annual sales by 2030.

Its $11.6 billion acquisition of migraine medication manufacturer Biohaven Pharmaceutical Holding (NASDAQ: BHVN) in May was the most recent in a series of purchases that also included Trillium Therapeutics and Arena Pharmaceuticals in recent years.

Oxbryta received approval last year for sickle cell disease management 

In 2019, the US government approved Global Blood’s Oxbryta to manage sickle cell disease in individuals aged 12 and over. The oral medication was approved in December 2021 to treat the illness in younger children. The drug’s sales increased by almost 50% to $194.7 million in 2021.

After a gloomy start to the calendar year, when a lack of significant purchases and clinical-stage treatment failures lowered investor morale and restricted funding, the biotech dealmaking pace has recently picked up again.

Also, Amgen Inc (NASDAQ: AMGN) also decided to purchase ChemoCentryx Inc on Thursday for $3.7 billion to obtain access to a possible breakthrough medication for inflammatory illnesses. AstraZeneca’s $39 billion acquisition of Alexion Pharmaceuticals in 2020 has put the realm of immune diseases in the limelight. The deal, which was announced before trading opened, will also give the corporation control of at least two investigational immune disorders medicines.

Please make sure to read and completely understand our disclaimer at While reading this article one must assume that we may be compensated for posting this content on our website.

The post Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion appeared first on Wall Street PR.

Read More

Continue Reading


AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkey Pox

By M. Marin
Expanding the Potential Indications for Hemopurifier Treatment
Aethlon Medical’s (NASDAQ: AEMD)…



By M. Marin



Expanding the Potential Indications for Hemopurifier Treatment

Aethlon Medical's (NASDAQ: AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro analysis, including COVID-19 and various variants and Monkey Pox, among others. The Aethlon Hemopurifier® is being studied in a severe COVID-19 clinical trial under the company's open IDE (Investigational Device Exemption) for life-threatening viral infections.

The safety and feasibility of the Hemopurifier is being evaluated in an Early Feasibility Study (EFS) that will enroll up to 40 COVID-19 ICU patients. The first patient was enrolled in this study in June 2022 and has completed the Hemopurifier treatment. AEMD has nine fully activated hospitals that are actively screening patients for the trial.

In addition to this study, the Hemopurifier has demonstrated positive results in two severely ill patients under individual emergency use and in in vitro analysis. The Hemopurifier has produced positive results in binding seven variants of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus in vitro, as discussed in an article1  that AEMD's CEO Dr. Charles J. Fisher Jr. and the company's Chief Medical Officer Dr. Steven LaRosa contributed to.

The company is also conducting a study of the impact of the ...

Full story available on

Read More

Continue Reading


Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via,

The Eurodollar curve…



Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via,

The Eurodollar curve implies four quarter-point cuts are on the way starting in 2023. The Fed believes otherwise. Let's discuss stock market implications.

Data from CME and Fed via Wall Street Journal.

Eurodollar Curve

The eurodollar curve has nothing to do with euros or dollars. Rather it is an interest rate curve and one of the world's most widely traded futures.

After peaking at about 3.9% this year, eurodollar betters believe the Fed will then cut rates all the way down to 2.8%. 

Five Not-Quite-Impossible Things the Market Believes

Wall Street Journal Contributor James Macintosh discussed the above chart in Five Not-Quite-Impossible Things the Market Believes

  1. Inflation is transitory. 

  2. The Fed realizes this in time.

  3. The jobs market cools enough to slow wage rises. 

  4. But not so much it means falling household spending.

  5. So consumer spending rises in real terms. 

In reference to the led chart, Macintosh says "The first assumption is the hardest to believe."

I disagree. The hardest thing to believe is the overall goldilocks scenario and that the current rally makes any sense at all. 

Inflation may easily come down if the Fed tightens too much too fast causing a severe recession. What would that do to corporate profits? 

But assume otherwise, that inflation does not come down more. What would that do to corporate profits? 

While any of the first three points may easily be correct, the combination of all five being correct and that stocks will rise in a goldilocks scenario is what I find hard to believe.

Is the Market Forward Looking?

Goldilocks proponents will tell you that the market is forward looking. 

The market isn't forward looking and never was. It is a coincident indicator of current sentiment, wildly wrong at major turns.

If the market was forward looking, what precisely was it looking forward to at the November 2007 peak with recession starting the next month? 

What was it looking forward to at the 1929 peak, the 1933 bottom, the 2009 bottom or any other top or bottom?

The Fed Will Hike Until It Breaks Something

I believe the eurodollar curve is more likely to be correct than the Fed. When has the Fed gotten much of anything correct?

The eurodollar view has two ways to win. The first is the Fed actually does tame inflation to the degree that it wants.

That's possible in a severe enough recession. And the global picture is easily weak enough for that to happen.

The second way the eurodollar curve might be correct is if the Fed breaks the credit market. 

The Fed would immediately reverse course, regardless of inflation, should that happen. 

Neither a credit event nor strong recession would be good for the stock market.

The least likely thing is that the Fed achieves a goldilocks soft landing. Yet, assume that happens. 

Macintosh says, and I agree, "The bull case that stocks and corporate bonds are pricing requires the combination of low joblessness and wage rises to allow spending to rise faster than inflation even after pandemic savings run out. But not so much faster that it hits capacity constraints and accelerates inflation."

The problem with goldilocks is stocks are priced so much beyond perfection that they may decline anyway. 

Globally Speaking 

  1. China Does Surprise Rate Cut to Help Its Economy, But It Won't Work

  2. German Costs to Ship by Barge are up Twenty Times and May Soon Be Impossible

  3. UK Average Electricity Cost Will Soar to $5,370 Per Year By 2023

  4. US Industries Are Buckling Under Pressure of Surging Electricity Costs

Good luck with goldilocks, especially with the Fed still hiking. 

*  *  *

Please Subscribe to MishTalk Email Alerts.

Tyler Durden Wed, 08/17/2022 - 09:45

Read More

Continue Reading